PDCD1 and cancer: Anti-PD-1 therapy and other checkpoint inhibitors are approved for the treatment of 14 cancer types, making around 39%3 of all cancer patients eligible for checkpoint therapy. Unfortunately, only approximately 11%3 of all cancer patients benefit from anti-PD-1 therapies.